Title:
CRYSTAL FORM OF TAVAPADON, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/143321
Kind Code:
A1
Abstract:
A new crystal form of tavapadon (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a dopamine D1/D5 receptor agonist drug and a drug for treating Parkinson's disease. The crystal form of the compound I has one or more improved properties than the prior art, solves the problems in the prior art, and is of great value to the optimization and development of the drug in the future.
Inventors:
QIN HAIYAN (CN)
SHI JIAMING (CN)
SHI JIAMING (CN)
Application Number:
PCT/CN2023/072961
Publication Date:
August 03, 2023
Filing Date:
January 18, 2023
Export Citation:
Assignee:
CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (CN)
International Classes:
C07D401/14; A61K31/513; A61P25/00; C07D405/14
Domestic Patent References:
| WO2015162518A1 | 2015-10-29 |
Foreign References:
| CN105324376A | 2016-02-10 | |||
| CN104981472A | 2015-10-14 | |||
| CN104837839A | 2015-08-12 |
Other References:
MARTINI, M. ET AL.: "Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity", ACS CHEMICAL NEUROSCIENCE, vol. 10, 6 August 2019 (2019-08-06), pages 4160 - 4182, XP055673903, DOI: 10.1021/acschemneuro.9b00410
Download PDF:
Previous Patent: LINKER FOR PREPARING ANTIBODY-DRUG CONJUGATE, COMPOUND, AND USE
Next Patent: P95HER2 ANTIBODY AND USE THEREOF
Next Patent: P95HER2 ANTIBODY AND USE THEREOF